CSL is a century-old company and a darling among healthcare stocks, having delivered a 15% annual return over the past 10 years.
Currently, investors are spooked by three risks that are getting lots of attention.
Risk 1: Weight-loss drugs
Ozempic improves glycaemic control and can be used 'off label' to assist weight loss.
While the drug has been around for years, it's making headlines because researchers are finding new applications for it and easier ways to administer it.
The risk that Ozempic-like drugs, known as GLP-1 agonists, pose to CSL can be split into broad and narrow effects.
On the broad side, Ozempic helps people lose weight by reducing appetite. Ozempic is currently very expensive, but we can imagine a future where the government subsidises the drug as a way to improve the population's overall health and take pressure off stressed healthcare budgets.
The relevance to CSL is that its sprawling network of plasma collection centres tends to focus on lower-income neighbourhoods.
However, individuals with lower incomes also face a higher risk of being overweight, so this demographic may benefit from Ozempic disproportionately.
If people on Ozempic spend less on food, and their discretionary incomes subsequently rise, the pool of willing plasma donors may decline, or CSL may need to increase donor fees to compensate.
We consider this scenario unlikely, but Ozempic could disrupt some of CSL's products directly, including in its Vifor division - chiefly iron and other therapies used by patients with chronic kidney disease (CKD) and its nephrology and cholesterol drugs.
This story is from the December/January 2023 edition of Money Magazine Australia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December/January 2023 edition of Money Magazine Australia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Is the public market shrinking?
Australia needs a healthy stock market to give companies access to funds and to allow retail investors to build wealth.
India: three steps to transformation
Massive investment and extensive reforms turbocharge the economy.
The ballet of business
Changing direction, products, models and marketing is a hard task for a business. We chart what it takes to turn a business around, plus profile four successful pivots.
Save money and the planet
Could the high cost of living give us the incentive we need to reduce how much water and energy we use or waste? These eco-friendly household tips will help you do just that.
AI adoption is the new black
Artificial intelligence is set to reshape the commercial world, and small enterprises can’t afford to miss the boat.
Spam attack! Murky laws jam our inboxes
Unwanted marketing material is one of the pain points of modern life.
From rags to riches in style
Rich Tran sported a bowl cut until he was 14 years old and had no intention of becoming a hairdresser.
New work deals are killing the 'old' office
The Covid pandemic and the subsequent lockdowns accelerated the trend to more people working from home. It was a mixed experience.
Points taken: the truth about rewards
Can hopping between credit cards really boost your frequent flyer haul and give you cheap or free travel - or is it doing more harm than good behind the scenes? Money puts it to the test.
Shortcuts to own a home
Innovative ideas with a focus on low costs and sustainability could help solve the housing crunch.